» Articles » PMID: 27581464

Disulfiram and Diphenhydramine Hydrochloride Upregulate MiR-30a to Suppress IL-17-Associated Autoimmune Inflammation

Overview
Journal J Neurosci
Specialty Neurology
Date 2016 Sep 2
PMID 27581464
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Unlabelled: T-helper 17 (Th17) cells play an important role in the pathogenesis of multiple sclerosis (MS), an autoimmune demyelinating disease that affects the CNS. In the present study, MicroRNA sequencing (miRNA-seq) was performed in mouse Th0 and Th17 cells to determine the critical miRNAs that are related to Th17 differentiation. We found that miR-30a was significantly downregulated during mouse Th17 differentiation. In addition, the level of miR-30a in CD4(+) T cells from peripheral blood of MS patients and experimental autoimmune encephalomyelitis (EAE) animal models was also decreased and inversely correlated with the expression of interleukin 17a, the canonical cytokine of Th17 cells. Moreover, overexpression of miR-30a inhibited Th17 differentiation and prevented the full development of EAE, whereas interference of miR-30a promoted Th17 differentiation. Mechanism studies showed that miR-30a reduced IRF4 expression by specifically binding with the 3'-untranslated region. Through screening of 640 different Food and Drug Administration (FDA)-approved drugs, we found that disulfiram and diphenhydramine hydrochloride were effective candidates for inhibiting Th17 differentiation and ameliorating EAE development through upregulating miR-30a. To our knowledge, the present work is not only the first miRNA-seq study focusing on Th17 differentiation, but also the first chemical screening for FDA-approved drugs that inhibit Th17 differentiation through regulating miRNA expression.

Significance Statement: The present work is the first miRNA sequencing (miRNA-seq) study focusing on T-helper 17 (Th17) differentiation. By miRNA deep sequencing, we found that miR-30a was downregulated during Th17 differentiation. miR-30a was also decreased in CD4(+) T cells from multiple sclerosis patients and experimental autoimmune encephalomyelitis (EAE) mice. miR-30a reduced IRF4 expression by specific binding with the 3'-untranslated region and thus suppressed Th17 differentiation and prevented the full development of EAE. Interestingly, by performing a chemical screen with Food and Drug Administration-approved small-molecule drugs, we found that disulfiram and diphenhydramine upregulated miR-30a and suppressed Th17-associated autoimmune demyelination.

Citing Articles

NLRP3 inflammasome in neuroinflammation and central nervous system diseases.

Xu W, Huang Y, Zhou R Cell Mol Immunol. 2025; .

PMID: 40075143 DOI: 10.1038/s41423-025-01275-w.


Inflammasomes in neurodegenerative diseases.

Wang Q, Yang S, Zhang X, Zhang S, Chen L, Wang W Transl Neurodegener. 2024; 13(1):65.

PMID: 39710713 PMC: 11665095. DOI: 10.1186/s40035-024-00459-0.


Microglial Mayhem NLRP3 Inflammasome's Role in Multiple Sclerosis Pathology.

Fan H, Fu Q, Du G, Qin L, Shi X, Wang D CNS Neurosci Ther. 2024; 30(12):e70135.

PMID: 39690733 PMC: 11652677. DOI: 10.1111/cns.70135.


Antifibrotic effect of disulfiram on bleomycin-induced lung fibrosis in mice and its impact on macrophage infiltration.

Okabe Y, Toda E, Urushiyama H, Terashima Y, Kunugi S, Kajimoto Y Sci Rep. 2024; 14(1):23653.

PMID: 39384840 PMC: 11464646. DOI: 10.1038/s41598-024-71770-z.


The multiple roles of interferon regulatory factor family in health and disease.

Wang L, Zhu Y, Zhang N, Xian Y, Tang Y, Ye J Signal Transduct Target Ther. 2024; 9(1):282.

PMID: 39384770 PMC: 11486635. DOI: 10.1038/s41392-024-01980-4.


References
1.
Matusevicius D, Kivisakk P, He B, Kostulas N, Ozenci V, Fredrikson S . Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler. 1999; 5(2):101-4. DOI: 10.1177/135245859900500206. View

2.
McDonald W, Compston A, Edan G, Goodkin D, Hartung H, Lublin F . Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001; 50(1):121-7. DOI: 10.1002/ana.1032. View

3.
Rengarajan J, Mowen K, McBride K, Smith E, Singh H, Glimcher L . Interferon regulatory factor 4 (IRF4) interacts with NFATc2 to modulate interleukin 4 gene expression. J Exp Med. 2002; 195(8):1003-12. PMC: 2193700. DOI: 10.1084/jem.20011128. View

4.
McManus M, Haines B, Dillon C, Whitehurst C, Van Parijs L, Chen J . Small interfering RNA-mediated gene silencing in T lymphocytes. J Immunol. 2002; 169(10):5754-60. DOI: 10.4049/jimmunol.169.10.5754. View

5.
Tominaga N, Ohkusu-Tsukada K, Udono H, Abe R, Matsuyama T, Yui K . Development of Th1 and not Th2 immune responses in mice lacking IFN-regulatory factor-4. Int Immunol. 2002; 15(1):1-10. DOI: 10.1093/intimm/dxg001. View